SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com/.
Baron Energy (OTCBB: BROE) $0.36. Announced yesterday that it has partnered with Newport Capital Consultants, Inc. to assist the Company with market strategy and recognition.
Management Comments.
Ronnie L. Steinocher, President and CEO of Baron Energy, commented; "Newport Capital Consultants has a long and successful track record of assisting small energy companies in increasing their market presence. Having a partner like Newport Capital will enable us to accelerate our growth plans, while generating considerable institutional and public awareness." Mr. Steinocher also noted, "This partnership will allow us to adjust our plans forward for the second half of the year, including additional acquisitions and in-fill drilling programs."
What They Do: Baron Energy is an independent oil and gas production, exploitation, and exploration company headquartered in Midland, Texas with producing assets in the prolific oil producing Permian Basin of West Texas.
Baron owns production that is 99% oil, both operated and non-operated, with working interest ranging from 5% to 100% in oil and gas fields located in Baylor, Borden, Garza, Jones, Runnels, Scurry and Taylor Counties, Texas.
Baron's growth strategy centers on making accretive property acquisitions in its core operating area. The Company targets properties that have oil production with upside developmental potential.
Labopharm Inc. (Nasdaq:DDSS) $1.54. Today announced along with Gruppo Angelini that they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the
"This joint venture builds on the foundation of mutual trust and a track record of execution that underlies the co-development relationship we established with Angelini more than four years ago," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We are very pleased with the opportunity to expand our existing relationship with Angelini, a company that has shown considerable growth as a result of its strong management and marketing expertise."
The joint venture, Angelini Labopharm, will be 50 percent owned by each of Labopharm and Angelini and will be initially managed by Mary Anne Heino, President of Labopharm's US Operations, and her team.
What They Do: Headquartered in Laval, Canada with US offices in Princeton, New Jersey, Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies.
IMAX Corporation (Nasdaq: IMAX) $20.30. Today announced adjusted EBITDA (as defined by the Company's credit facility) of $42.0 million and $93.4 million for the first quarter and last twelve months ended March 31, 2010, respectively, compared to $
What They Do: IMAX Corporation is one of the world's leading entertainment technology companies, specializing in immersive motion picture technologies.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview. SmallCapReview has been compensated five thousand dollars for its efforts with regards to Baron Energy by a third party AWT. SCR is not a Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports released to the public through this website, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes.
